Hematopoietic stem cell transplantation in Egypt

Bone Marrow Transplantation
H K MahmoudA Sultan

Abstract

Hematopoietic SCT is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 18 years of experience and more than 1300 transplants, this article will focus on special issues, which we think are important for hematopoietic SCT practices in developing countries, taking the program in Egypt as an example that may be applicable to other countries in the developing world. The SCT program in Egypt started in 1989 on a narrow scale. In 1997, the transplant rate increased dramatically with the opening of the SCT unit at the Nasser Institute. Our team is registered in the Center for International Blood and Marrow Transplant Research. The total number of transplants performed till June 2007 is 1362; 80% of the cases are allogeneic and 20% autologous. There are seven other centers in Egypt performing mainly autologous transplants.

References

May 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H M ShulmanG B McDonald
Jul 21, 1998·Annals of the New York Academy of Sciences·C Politis
May 29, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S I StrasserG B McDonald
Jul 8, 1999·The New England Journal of Medicine·N F Olivieri
Jun 28, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F Abdel-AzizI Sallam
Dec 22, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M HabibI Sallam
Dec 25, 2004·European Journal of Gastroenterology & Hepatology·Manal H El-SayedHossam K Mahmoud

❮ Previous
Next ❯

Citations

Jan 23, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rajat KumarWael Saber
Jan 30, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Mahmoud AljurfHassan El Solh
Dec 2, 2011·Annals of the New York Academy of Sciences·Mohamed-Ridha BarboucheAhmed Aziz Bousfiha
Feb 18, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Monica M MatsumotoKirstin R W Matthews
Mar 29, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Syed O A AhmedMahmoud Aljurf
Apr 8, 2016·Blood·Matthew C Canver, Stuart H Orkin
Sep 13, 2016·Bone Marrow Transplantation·A A HusseinUNKNOWN Pediatric Cancer Working Committee of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group
Aug 15, 2009·Current Opinion in Hematology·Alois Gratwohl, Helen Baldomero
Sep 7, 2017·Current Opinion in Hematology·Rajat KumarBiju George

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.